| Literature DB >> 26243484 |
Kelly Fellows1, Tomas Uher2, Richard W Browne3, Bianca Weinstock-Guttman4, Dana Horakova2, Helena Posova5, Manuela Vaneckova6, Zdenek Seidl6, Jan Krasensky6, Michaela Tyblova2, Eva Havrdova2, Robert Zivadinov7, Murali Ramanathan8.
Abstract
The purpose of this work was to investigate the associations of serum cholesterol and apolipoproteins with measures of blood-brain barrier (BBB) permeability and CNS inflammation following the first clinical demyelinating event. This study included 154 patients [67% female; age, 29.5 ± 8.2 years (mean ± SD)] enrolled in a multi-center study of interferon β1-a treatment following the first demyelinating event. Blood and cerebrospinal fluid (CSF) were obtained at screening prior to treatment. A comprehensive serum lipid profile and multiple surrogate markers of BBB breakdown and CNS immune activity were obtained. Higher levels of serum HDL cholesterol (HDL-C) and ApoA-I were associated with lower CSF total protein level, CSF albumin level, albumin quotient, and CSF IgG level (all P ≤ 0.001 for HDL-C and all P < 0.01 for ApoA-I). HDL-C was also associated with CSF CD80+ (P < 0.001) and with CSF CD80+CD19+ (P = 0.007) cell frequencies. Higher serum HDL is associated with lower levels of BBB injury and decreased CD80+ and CD80+CD19+ cell extravasation into the CSF. HDL may potentially inhibit the initiation and/or maintenance of pathogenic BBB injury following the first demyelinating event.Entities:
Keywords: apolipoproteins; cholesterol; clinically isolated syndrome; high density lipoprotein
Mesh:
Substances:
Year: 2015 PMID: 26243484 PMCID: PMC4583090 DOI: 10.1194/jlr.M060970
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922